About: Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed method review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed method review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed method review
Creator	Zhang, Yong Goh, W Miguel, Robby Student, Tcm Tai, Tay, Louisa Wong, Lin Wong, Pang Zhou, Ruishu
source	MedRxiv
abstract	Background: Coronavirus disease 2019 (COVID-19) is a pandemic affecting millions around the world. There is no existing pharmaceutical treatment that is known to be effective. Preliminary data shows that San Yao San Fang (SYSF) has clinical benefits in patients with COVID-19. The aim of this paper is to review existing data regarding the use of formulas within San Yao San Fang in the treatment of COVID-19 Search Strategy: We searched through 5 databases for studies on SYSF and patients with COVID-19 through April 2020. Eligibility Criteria: We included studies that included formulas within San Yao San Fang with or without Western interventions against Western interventions. Main results: We included 7 studies involving 532 patients. SYSF combined with Western interventions improved the recovery rate of symptoms such as fever (Risk Ratio (RR) 0.40 (95% CI 0.24 to 0.66, P < 0.01)), cough (RR 0.56 (95% CI 0.38 to 0.82, P < 0.01)) and fatigue (RR 0.61 (95% CI 0.47 to 0.78, P < 0.01)) and other symptoms such as headache, gastrointestinal symptoms, myalgia, dyspnoea and chest tightness (RR 0.63 (95% CI 0.47 to 0.83, P < 0.01)) as compared to the control group. SYSF combined with Western interventions reduced the duration of fever as compared to the control group. (Mean difference (MD) -1.18 (95% CI -1.45 to -0.91, P < 0.01)) In regards to adverse events, there is no statistical difference between the treatment group and the control group. (RR 1.62 (95% CI 0.83 to 3.17, P = 0.16)). SYSF combined with Western interventions did not show to significantly reduce duration of hospitalisation as compared to the control group. (MD -0.73 (95% CI -5.19 to 3.73, P = 0.75)) Conclusion: SYSF appears to be clinically effective and safe. Further research is required to ensure the efficacy of SYSF.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1101/2020.05.11.20098111
has license	medrxiv
sha1sum (hex)	3a5060a65d60e1d373a6b78a4af7f40d97685a32
schema:url	https://doi.org/10.1101/2020.05.11.20098111
resource representing a document's title	Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed method review
resource representing a document's body	covid:3a5060a65d60e1d373a6b78a4af7f40d97685a32#body_text
is schema:about of	named entity 'Western medicine' named entity 'COVID-19' named entity 'coronavirus disease 2019' named entity 'coronavirus disease 2019' named entity 'Chinese herbs' named entity 'statistically significant' named entity '95% CI' named entity 'death rates' named entity 'CRP' named entity 'fatigue' named entity 'Western medicine' named entity 'intravenous' named entity '95% CI' named entity 'HIF-1' named entity 'comorbidities' named entity '0.01' named entity 'preprint' named entity 'myalgia' named entity 'RCTs' named entity 'subgroup analysis' named entity 'MCP-1' named entity 'prospective studies' named entity 'retrospective studies' named entity 'treatment group' named entity 'IL-6' named entity 'hypertension' named entity 'medRxiv' named entity 'Hypothesis tests' named entity '1.06' named entity 'fever' named entity 'CC-BY 4.0 International license' named entity 'statistical difference' named entity 'fatigue' named entity 'headache' named entity 'gastrointestinal symptoms' named entity 'treatment group' named entity 'preprint' named entity 'SARS' named entity 'Risk Ratio' named entity 'April 2020' named entity 'Western medicine' named entity 'Umifenovir' named entity 'Treatment group' named entity 'Western medicine' named entity 'clinical treatment' named entity 'control group' named entity 'preprint' named entity 'Western medicine' named entity '95% CI' named entity 'diarrhoea' named entity 'sore throat' named entity 'preprint' named entity 'control group' named entity '95% CI' named entity 'COVID-19' named entity 'fever' named entity 'control group' named entity 'observational studies' named entity 'medRxiv' named entity 'statistically significant' named entity 'Wuhan' named entity 'preprint' named entity 'prospective study' named entity 'China National Knowledge Infrastructure' named entity 'medRxiv' named entity 'China' named entity 'CC-BY 4.0 International license' named entity 'Western medicine' named entity 'headache' named entity 'Remdesivir' named entity 'fatigue' named entity 'preprint' named entity 'risk ratio' named entity 'control group' named entity 'COVID' named entity 'headache' named entity 'control group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software